کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1397560 | 1501178 | 2011 | 8 صفحه PDF | دانلود رایگان |
Preliminary studies have shown the potential application for the diagnosis of Rheumatoid Arthritis (RA) patients with a severe disease course of an epitopic domain of β-fibrin. The aim of the present work was the analysis of the presence of antibodies against several β-fibrin synthetic peptides in relation to the immunogenetic background and disease course in a clinically well-defined RA patient cohort. Our results indicated that positive patients against anti-β-fibrin synthetic peptides have a higher percentage of HLA-DRB1 shared epitope (SE) than negative patients. We also observed that the presence of SE alleles was significantly associated with a higher level of anti-[Cit376]βfib(365–383) antibodies. When analyzing the effect of different SE alleles, we found a significant positive association between carriers of QRRAA allele and [Cit376]βfib(365–383) (Odds ratio 3.77; CI95%: 1.41–10.08). These results suggest that the anti-β-fibrin status is associated with the immunogenetic background of RA patients.
Figure optionsDownload as PowerPoint slideResearch highlights
► Analysis of antibodies against β-fibrin synthetic peptides.
► Association with the immunogenetic background and disease course of RA patients.
► SE alleles significantly associate with anti-[Cit376]βfib(365–383) antibodies.
► Significant association between carriers of QRRAA allele and [Cit376]βfib(365–383).
Journal: European Journal of Medicinal Chemistry - Volume 46, Issue 4, April 2011, Pages 1095–1102